Carta al Editor
Trombocitopenia por omalizumab
Thrombocytopenia due to omalizumab
Leído
8773
Vecesse ha leído el artículo
2721
Total PDF
6052
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 35 | 43 | 78 |
| 2025 5 | 139 | 26 | 165 |
| 2025 4 | 99 | 24 | 123 |
| 2025 3 | 90 | 24 | 114 |
| 2025 2 | 93 | 24 | 117 |
| 2025 1 | 72 | 31 | 103 |
| 2024 12 | 67 | 29 | 96 |
| 2024 11 | 69 | 64 | 133 |
| 2024 10 | 56 | 41 | 97 |
| 2024 9 | 58 | 33 | 91 |
| 2024 8 | 97 | 62 | 159 |
| 2024 7 | 107 | 37 | 144 |
| 2024 6 | 132 | 43 | 175 |
| 2024 5 | 90 | 29 | 119 |
| 2024 4 | 76 | 39 | 115 |
| 2024 3 | 65 | 24 | 89 |
| 2024 2 | 92 | 22 | 114 |
| 2024 1 | 77 | 12 | 89 |
| 2023 12 | 130 | 19 | 149 |
| 2023 11 | 112 | 17 | 129 |
| 2023 10 | 67 | 36 | 103 |
| 2023 9 | 59 | 19 | 78 |
| 2023 8 | 63 | 22 | 85 |
| 2023 7 | 59 | 25 | 84 |
| 2023 6 | 59 | 22 | 81 |
| 2023 5 | 59 | 21 | 80 |
| 2023 4 | 31 | 23 | 54 |
| 2023 3 | 68 | 42 | 110 |
| 2023 2 | 70 | 38 | 108 |
| 2022 1 | 57 | 46 | 103 |
| 2022 12 | 54 | 43 | 97 |
| 2022 11 | 87 | 55 | 142 |
| 2022 10 | 71 | 49 | 120 |
| 2022 9 | 51 | 39 | 90 |
| 2022 8 | 49 | 53 | 102 |
| 2022 7 | 28 | 32 | 60 |
| 2022 6 | 44 | 37 | 81 |
| 2022 5 | 60 | 30 | 90 |
| 2022 4 | 35 | 38 | 73 |
| 2022 3 | 57 | 36 | 93 |
| 2022 2 | 58 | 31 | 89 |
| 2021 1 | 55 | 51 | 106 |
| 2021 12 | 61 | 36 | 97 |
| 2021 11 | 47 | 30 | 77 |
| 2021 10 | 55 | 45 | 100 |
| 2021 9 | 49 | 47 | 96 |
| 2021 8 | 47 | 29 | 76 |
| 2021 7 | 35 | 31 | 66 |
| 2021 6 | 33 | 36 | 69 |
| 2021 5 | 43 | 31 | 74 |
| 2021 4 | 112 | 77 | 189 |
| 2021 3 | 70 | 27 | 97 |
| 2021 2 | 50 | 31 | 81 |
| 2020 1 | 52 | 25 | 77 |
| 2020 12 | 48 | 38 | 86 |
| 2020 11 | 50 | 29 | 79 |
| 2020 10 | 37 | 13 | 50 |
| 2020 9 | 46 | 10 | 56 |
| 2020 8 | 38 | 10 | 48 |
| 2020 7 | 40 | 25 | 65 |
| 2020 6 | 53 | 27 | 80 |
| 2020 5 | 44 | 13 | 57 |
| 2020 4 | 51 | 14 | 65 |
| 2020 3 | 55 | 25 | 80 |
| 2020 2 | 38 | 7 | 45 |
| 2020 1 | 39 | 15 | 54 |
| 2019 12 | 54 | 23 | 77 |
| 2019 11 | 31 | 16 | 47 |
| 2019 10 | 50 | 11 | 61 |
| 2019 9 | 42 | 7 | 49 |
| 2019 8 | 45 | 18 | 63 |
| 2019 7 | 37 | 17 | 54 |
| 2019 6 | 53 | 16 | 69 |
| 2019 5 | 106 | 28 | 134 |
| 2019 4 | 89 | 19 | 108 |
| 2019 3 | 44 | 21 | 65 |
| 2019 2 | 30 | 15 | 45 |
| 2019 1 | 44 | 18 | 62 |
| 2018 12 | 38 | 19 | 57 |
| 2018 11 | 59 | 25 | 84 |
| 2018 10 | 87 | 13 | 100 |
| 2018 9 | 53 | 14 | 67 |
| 2018 8 | 1 | 0 | 1 |
| 2018 7 | 3 | 0 | 3 |
| 2018 6 | 4 | 0 | 4 |
| 2018 5 | 8 | 0 | 8 |
| 2018 4 | 36 | 0 | 36 |
| 2018 3 | 55 | 0 | 55 |
| 2018 2 | 20 | 0 | 20 |
| 2018 1 | 18 | 0 | 18 |
| 2017 12 | 19 | 0 | 19 |
| 2017 11 | 17 | 0 | 17 |
| 2017 10 | 18 | 0 | 18 |
| 2017 9 | 21 | 0 | 21 |
| 2017 8 | 24 | 0 | 24 |
| 2017 7 | 17 | 1 | 18 |
| 2017 6 | 32 | 10 | 42 |
| 2017 5 | 41 | 12 | 53 |
| 2017 4 | 32 | 6 | 38 |
| 2017 3 | 25 | 6 | 31 |
| 2017 2 | 71 | 3 | 74 |
| 2016 1 | 16 | 2 | 18 |
| 2016 12 | 47 | 14 | 61 |
| 2016 11 | 67 | 25 | 92 |
| 2016 10 | 97 | 10 | 107 |
| 2016 9 | 117 | 1 | 118 |
| 2016 8 | 14 | 5 | 19 |
| 2016 7 | 14 | 13 | 27 |
| 2016 6 | 1 | 9 | 10 |
| 2016 5 | 0 | 11 | 11 |
| 2016 4 | 1 | 17 | 18 |
| 2016 3 | 0 | 24 | 24 |
| 2016 2 | 0 | 9 | 9 |
| 2015 1 | 1 | 12 | 13 |
| 2015 12 | 1 | 13 | 14 |
| 2015 11 | 0 | 19 | 19 |
| 2015 10 | 1 | 23 | 24 |
| 2015 9 | 2 | 0 | 2 |
| 2015 8 | 2 | 17 | 19 |
| 2015 7 | 1 | 0 | 1 |
| 2015 6 | 1 | 0 | 1 |
| 2015 5 | 1 | 7 | 8 |
| 2015 4 | 2 | 0 | 2 |
| 2015 3 | 4 | 3 | 7 |
| 2015 2 | 3 | 2 | 5 |
| 2015 1 | 2 | 1 | 3 |
| 2014 12 | 5 | 1 | 6 |
| 2014 11 | 2 | 1 | 3 |
| 2014 10 | 4 | 1 | 5 |
| 2014 9 | 5 | 1 | 6 |
| 2014 8 | 8 | 1 | 9 |
| 2014 7 | 9 | 3 | 12 |
| 2014 6 | 101 | 55 | 156 |
| 2014 5 | 9 | 1 | 10 |
Mostrar todo
